Dashboard
Manage Tickers

SNY Sanofi

Nasdaq sanofi.com


$ 51.62 $ 2.12 (4.28 %)    

Friday, 24-Oct-2025 19:49:08 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 51.64
$ 51.70
$ 50.25 x 6
$ 52.34 x 18
$ 51.25 - $ 52.20
$ 43.86 - $ 57.56
4,635,116
na
65.23B
$ 0.51
$ 11.33
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

dupixent-pushes-sanofis-quarterly-sales-past-145-billion-mark
Dupixent Pushes Sanofi's Quarterly Sales P...
10/24/2025 14:47:19

Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth expe...

Core News & Articles
Earnings Scheduled For October 24, 2025
10/24/2025 08:32:15

sanofi-maintains-2025-guidance-anticipates-high-single-digit-sales-growth-at-constant-exchange-rates-and-strong-low-double-digit-eps-rebound
Sanofi Maintains 2025 Guidance, Anticipate...
10/24/2025 05:47:22

Guidance unchangedIn 2025, sales are anticipated to grow by a high single-digit percentage at CER. Sanofi confirms the expectat...

sanofi-q3-adj-eps-170-beats-160-estimate-sales-14538b-beat-14460b-estimate
Sanofi Q3 Adj. EPS $1.70 Beats $1.60 Estim...
10/24/2025 05:43:20

Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.60 by 6.31 p...

oil-stocks-rally-on-trumps-russia-sanctions-whats-moving-markets-thursday
Oil Stocks Rally On Trump's Russia Sanctio...
10/23/2025 16:55:59

Energy markets dominated headlines Thursday as a fresh wave of U.S. sanctions targeting Russia's oil giants sparked a sharp...

examining-the-future-sanofis-earnings-outlook
Examining the Future: Sanofi's Earnings Ou...
10/23/2025 14:00:55

medidata-sanofi-expand-collaboration-over-clinical-research
Medidata, Sanofi Expand Collaboration Over...
10/23/2025 10:14:09

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi ...

Core News & Articles
Sanofi Strengthens Alliance With Medidata ...
10/23/2025 05:41:05

sanofi-drug-shows-superior-efficacy-in-genetic-disease-compared-to-current-standard-therapy
Sanofi Drug Shows Superior Efficacy In Gen...
10/22/2025 19:16:58

Sanofi revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101).

sanofi-reports-positive-phase-2-elevaate-results-showing-efdoralprin-alfas-superiority-over-weekly-plasma-derived-therapy-in-aatd-emphysema-patients
Sanofi Reports Positive Phase 2 ElevAATe R...
10/22/2025 05:40:04

Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 s...

sanofis-fluzone-high-dose-demonstrates-319-reduction-in-influenza-hospitalizations-in-seniors---flunity-hd-data-published-in-lancet
Sanofi's Fluzone High-Dose Demonstrates 31...
10/21/2025 17:57:43

Compared to standard-dose influenza vaccines, Fluzone High-Dose Influenza Vaccine demonstrated a reduction in laboratory-confir...

sanofis-tzield-accepted-for-expedited-review-in-the-us-for-stage-3-type-1-diabetes-through-fda-commissioners-national-priority-voucher-pilot-program
Sanofi's Tzield Accepted For Expedited Rev...
10/20/2025 13:17:48

If approved, Tzield would be the first disease-modifying therapy to delay the progression of stage 3 T1D in adults and pediatri...

alphamedix-shows-durable-clinically-meaningful-responses-in-advanced-gep-nets-meeting-all-primary-endpoints-in-phase-2-study
AlphaMedix Shows Durable, Clinically Meani...
10/20/2025 06:44:38

ESMO: AlphaMedix phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroend...

sanofis-rezurock-approval-stumbles-in-eu-for-chronic-graft-vs-host-disease
Sanofi's Rezurock Approval Stumbles In EU ...
10/17/2025 17:03:37

CHMP rejects Sanofi's Rezurock for chronic GVHD in the EU, while approving Wayrilz for ITP, highlighting mixed outcomes for...

fda-unveils-first-experimental-drugs-under-fast-track-voucher-plan-to-cut-drug-review-times
FDA Unveils First Experimental Drugs Under...
10/17/2025 14:03:18

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, a...

Core News & Articles
Sanofi Seeks Re-Examination Following Nega...
10/17/2025 11:07:44

evoq-therapeutics-partners-with-sanofi-in-500m-deal-to-deliver-transformative-autoimmune-treatments
EVOQ Therapeutics Partners With Sanofi In ...
10/16/2025 10:06:59

hedge-fund-shah-capital-urges-novavax-to-consider-sale-amid-vaccine-rollout-struggles-sees-5-billion-potential
Hedge Fund Shah Capital Urges Novavax To C...
10/14/2025 17:08:17

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...

sanofi-alphamedix-study-hits-key-milestones-in-phase-2-study
Sanofi AlphaMedix Study Hits Key Milestone...
10/08/2025 13:04:07

Sanofi reports that its AlphaMedix phase 2 trial showed strong efficacy and survival benefits in gastroenteropancreatic neuroen...

sanofi-and-orano-meds-alphamedixtm-meets-all-primary-efficacy-endpoints-in-phase-2-gep-net-study
Sanofi And Orano Med's AlphaMedixTM Meets ...
10/08/2025 05:55:08

AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful be...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION